1787 related articles for article (PubMed ID: 793446)
1. The influence of pharmaceutical compounds on male fertility.
Neumann F; Diallo FA; Hasan SH; Schenck B; Traore I
Andrologia; 1976; 8(3):203-35. PubMed ID: 793446
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
Guerin JF; Rollet J
Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
[TBL] [Abstract][Full Text] [Related]
3. Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men.
Moltz L; Römmler A; Post K; Schwartz U; Hammerstein J
Contraception; 1980 Apr; 21(4):393-413. PubMed ID: 6771095
[TBL] [Abstract][Full Text] [Related]
4. Endogenous antispermatogenic agents: prospects for male contraception.
Ewing LL; Robaire B
Annu Rev Pharmacol Toxicol; 1978; 18():167-87. PubMed ID: 206192
[TBL] [Abstract][Full Text] [Related]
5. Target sites for suppressing fertility in the male.
Prasad MR; Rajalakshmi M
Adv Sex Horm Res; 1976; 2():263-87. PubMed ID: 797248
[TBL] [Abstract][Full Text] [Related]
6. Developments in the control of testicular function.
Swerdloff RS; Wang C; Bhasin S
Baillieres Clin Endocrinol Metab; 1992 Apr; 6(2):451-83. PubMed ID: 1377467
[TBL] [Abstract][Full Text] [Related]
7. Development of male-fertility-regulating agents.
Ray S; Verma P; Kumar A
Med Res Rev; 1991 Sep; 11(5):437-72. PubMed ID: 1943328
[TBL] [Abstract][Full Text] [Related]
8. Endocrine approaches to male fertility control.
Knuth UA; Nieschlag E
Baillieres Clin Endocrinol Metab; 1987 Feb; 1(1):113-31. PubMed ID: 3297020
[TBL] [Abstract][Full Text] [Related]
9. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment.
Soufir JC; Jouannet P; Marson J; Soumah A
Acta Endocrinol (Copenh); 1983 Apr; 102(4):625-32. PubMed ID: 6221496
[TBL] [Abstract][Full Text] [Related]
10. Use of low-dosage oral cyproterone acetate as a male contraceptive.
Wang C; Yeung KK
Contraception; 1980 Mar; 21(3):245-72. PubMed ID: 6771091
[TBL] [Abstract][Full Text] [Related]
11. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
Behre HM; Nashan D; Hubert W; Nieschlag E
J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
[TBL] [Abstract][Full Text] [Related]
12. The regulation of male fertility: the state of the art and future possibilities.
de Krester DM
Contraception; 1974 Jun; 9(6):561-600. PubMed ID: 4614937
[TBL] [Abstract][Full Text] [Related]
13. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
Wallace EM; Gow SM; Wu FC
J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
[TBL] [Abstract][Full Text] [Related]
14. In vitro steroid metabolic studies in human testes I: Effects of estrogen on progesterone metabolism.
Rodriguez-Rigau LJ; Tcholakian RK; Smith KD; Steinberger E
Steroids; 1977 Jun; 29(6):771-86. PubMed ID: 910250
[TBL] [Abstract][Full Text] [Related]
15. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
[TBL] [Abstract][Full Text] [Related]
17. Low dose of cyproterone acetate and testosterone enanthate for contraception in men.
Meriggiola MC; Bremner WJ; Costantino A; Di Cintio G; Flamigni C
Hum Reprod; 1998 May; 13(5):1225-9. PubMed ID: 9647551
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity.
Phillips A; Hahn DW; McGuire JL
Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1191-6. PubMed ID: 1415445
[TBL] [Abstract][Full Text] [Related]
19. Male contraception: current status and future prospects.
Wu FC
Clin Endocrinol (Oxf); 1988 Oct; 29(4):443-65. PubMed ID: 3075164
[TBL] [Abstract][Full Text] [Related]
20. Hormones and hormonal target cells in the testis.
Hansson V; Djoseland O; Torgersen O; Ritzen EM; French FS; Nayfeh SN
Andrologia; 1976; 8(3):195-202. PubMed ID: 187086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
